This spring, the U.S. Food and Drug Administration is poised to make pivotal decisions on several new therapies that could transform care for patients with difficult-to-treat conditions, from hypertension to hepatitis D.
Among the most anticipated is Baxdrostat, an oral medication for treatment-resistant hypertension. This condition, defined as blood pressure that remains high despite the use of at least three different medications, leaves patients with few alternatives. Baxdrostat works by uniquely inhibiting the aldosterone synthase enzyme, a novel mechanism not found in current treatments. If approved, it would offer a crucial new add-on therapy for a population that has effectively run out of options.
For Alzheimer's disease, a new formulation could significantly improve access. Leqembi Iqlik, a weekly injectable version of the existing IV therapy Leqembi, is under review for initial treatment of early Alzheimer's. Approval would mark the first time patients could begin this type of disease-modifying therapy with at-home administration, eliminating the frequent burden of traveling to an infusion center. This shift could make pursuing treatment a more viable path for many patients and their caregivers.
In a landmark move, the injectable drug Hepcludex (bulevirtide) could become the first FDA-approved treatment for chronic hepatitis D virus infection, a serious liver condition that currently has no approved therapies in the United States. Clinical data suggests the most effective approach may combine Hepcludex with another medication, pegylated interferon, offering a long-awaited treatment strategy for a neglected patient community.
Finally, a new aid for smoking cessation may soon be available. Cytisinicline is an oral, non-nicotine prescription therapy designed to help adults quit smoking. It would join the small roster of drugs like varenicline that work by targeting nicotine dependence in the brain. The therapy is designed for either a six- or 12-week course, providing another valuable tool in a clinician's arsenal to match individual patient needs.
With decisions expected in the coming months, these therapies collectively signal progress across the medical landscape. They offer the promise of first-ever treatments, novel mechanisms of action, and enhanced convenience, giving healthcare providers and patients more avenues to achieve better health outcomes.